![Spring Bank Corporate Vision ,[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Similar to Spring Bank Presentation Jan 09
Similar to Spring Bank Presentation Jan 09 (20)
Spring Bank Presentation Jan 09
- 1. Nucleic Acid Chemistry for a New Generation of Pharmaceuticals Corporate Presentation Confidential
- 7. Spring Bank Technology Platform – Strong Competitive Advantages Nucleoside/Nucleotide Analogs Immune Modulators RNAi/Antisense SB 9000 Mechanism of Action Chain terminators –target HBV/HCV polymerase Activate natural immune response Complementary RNA strands bind with viral DNA/RNA Targets viral DNA primer that initiates viral replication Major Drawbacks Viral mutation and resistance/Toxicity Toxicity/Delivery Delivery/Toxicity N/A Delivery Oral Injection Injection Oral Viral mutation/resistance Yes Not known Yes No Combination Therapy Limited Options Required Not known Possible Toxicity Significant Significant Significant Non-toxic, not metabolized by liver Cyt P 450 Long Term Administration No/Toxic No/Toxic No/Toxic Probable Manufacturing Economical/scalable Expensive/difficult Need to develop specialized facility Economical/scalable
- 13. Oral SB 9000 Prodrug Shows Potent Antiviral Activity in 14-Day Transgenic Mouse Model Southern Blot Analysis of Liver HBV DNA Treated Control EC 50 < 3mg/Kg
- 16. SB 9200 Shows Potent Anti-HCV Activity In Vitro * Replicon cell line containing H/FL-Neo (genotype 1a (H77), full length construct) (Blight, et al., 2003, J. Virol. 77:3181) **Replicon cell line AVA5 (sub-genomic (CON1), genotype 1b; (Blight, et al., 2000, Science 290:1972) EC 50 and EC 90 are drug concentrations which results in a 2-fold, or a 10-fold depression of intracellular HCV RNA relative to that of the untreated controls [ Dot blot hybridization assay normalized to b-actin RNA]. Inhibition of HCV Replication Using the Replicon Assay Viral Genotype Compound 1A* 1B** EC 50 EC 90 EC 50 EC 90 micromolar micromolar SB 9200 2.2 8 1 6 SB 9400 NA NA 0.16 NA SB 9300 2.9 8.5 3.2 NA Interferon (alFNB2) U/mL 1.8 8.0 2 8.5 2C Me Cyt (NM 283) 1.6 6.2 NA NA
- 17. SB 9200 Has Demonstrated Synergy with Several Drug Combinations in Vitro 1 1 In collaboration with Brent Korba, Georgetown University Drug EC 50 (uM) Ratio EC 50 Comb (uM) Comments SB 9200 1.5 - 2.3 +Interferon α 2.1 3:1 1:1 1:3 0.662 0.643 0.658 Synergistic Synergistic Synergistic +Ribavirin >30 1:30 2.3 Synergistic +Ribavirin + interferon α 3:1 1:1 1:3 0.777 0.629 0.686 Synergistic Synergistic Synergistic + 2C Me Cyt (NM 283) 1.4 3:1 1:1 1:3 0.522 0.494 0.462 Synergistic Synergistic Additive +Vertex (telaprevir) 0.250 (CC 50 <80) 100:1 30:1 10:1 0.108 0.126 0.118 Synergistic Synergistic Synergistic
- 19. Management Douglas Jensen Co-founder & CEO Co-founder and CEO, Origenix Technologies VP Administration & Corporate Development, Hybridon Sr. VP Oppenheimer & Company R.P. (Kris) Iyer, Ph.D. Co-founder & CSO Co-founder & VP Discovery, Origenix Senior Scientist & Associate Director of the Discovery Program and Technology Development, Hybridon Don Mitchell, MBA VP Corporate Development, CCO Exec Director, Corp Development, Idenix Pharmaceuticals Director of Marketing/Strategic Planning, Amgen Principal Consultant, PricewaterhouseCoopers Director, Marketing/Business Development, Novartis Academic Collaborators Professor Brent Korba, Ph.D. Georgetown University (HBV, HCV) Professor John Morrey, Ph.D. Utah State University (HBV) Professor Nigel Bourne, Ph.D. University of Texas (HCV) Professor Norman Kneteman, Ph.D. University of Alberta, KMT Hepatech
Editor's Notes
- We have described our company as the Nucleotide Company because we have created a unique drug discovery platform that is focused exclusively on the discovery and development of novel small molecule drugs based on nucleotide chemistry. Platform produces a totally new class of natural–like nucleotide compounds that inherently have many desirable characteristics. Effective for targeting disease, non-toxic, multiple routes of administration including oral and can be designed for treatment of multiple therapeutic indications such as Our internal focus initially on the development of new class of drugs for the treatment of Hepatitis B & C and we have drug candidates in late stage preclinical development for both indications. Excellent Preclinical Results. Very potent against wild type and resistant strains of these viruses, non-toxic up to very high doses, can be used safely and effectively with other classes of drugs NIH has committed $7 million very strong validation of our app
- We have described our company as the Nucleotide Company because we have pioneered a unique drug discovery platform that is focused exclusively on the discovery and development of novel small molecule drugs based on nucleotide chemistry. Traditional pharma stayed away from this chemistry difficult, expensive and according to their paradigm not well suited for small molecule therapeutics; can’t be made into oral drugs, manufacturing major challenge, Already met these challenges Platform produces a totally new class of natural–like nucleotide compounds that inherently have many desirable characteristics. Effective for targeting disease, non-toxic, multiple routes of administration including oral and can be designed for treatment of multiple therapeutic indications such as Our internal focus initially on the development of new class of drugs for the treatment of Hepatitis B & C and we have drug candidates in late stage preclinical development for both indications. Excellent Preclinical Results. Very potent against wild type and resistant strains of these viruses, non-toxic up to very high doses, can be used safely and effectively with other classes of drugs NIH has committed $7 million very strong validation of our app
- How familiar are you with this paradigm? This is natural paradigm that drives all drug discovery and development With this technology platform we have the ability to engineer smart molecules that can target nucleic acids and or proteins involved in the disease process
- Nucleotide platform produces family of compounds that will have consistent biological properties and superior pharmaceutical attributes regardless of the disease target. Compounds will share similar safety and ADME profiles, for example which will be well characterized and well understood which in turn will reduce development risk, shorten time to market and significantly reduce costs. Naturally occurring nucleotides routinely interact with proteins and nucleic acids in the body to perform a number of important cellular functions such as biochemical reactions, cell signaling and as a source of energy. SBP designs its nucleotide compounds to closely mimic these natural interactions
- Compared with other classes of drugs for the treatment of HBV, SB 9000 stands out as a unique therapeutic option. Unique mechanism of action Oral delivery Effective against mutant strains Can be used in combinations safely and effectively Non-toxic Because of these features with stand the rigors of long term administration Proprietary manufacturing in place both economical and scalable for commercial application.
- It is now estimated to be about 375 million patients worldwide who have carried the Hepatitis B surface antigen for 6 months or more and have not yet seroconverted. The areas of greatest endemicity include South East Asia and the Western Pacific and Africa countries around the Mediterranean. There are 2 – 3 million new chronically HBV infected patients each year and 1.3 – 1.5 million of the overall population die each year due to chronic Hep B disease.
- Platform rich in assets that can be leveraged through partnerships licensing agreements to generate non dilutive revenues – off set risk, create financial stability, leverage value to current stakeholders
- Why I am qualified to manage the company. Kris’s pedigree in Nucleic acid field – major contributor and innovator in field World class laboratories through NIH relationship
- Momentum and Validation Partnership model for revenue generation in motion